HP 228

Drug Profile

HP 228

Latest Information Update: 13 Aug 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SYGNIS Pharma
  • Developer Dura Pharmaceuticals; SYGNIS Pharma
  • Class Peptides
  • Mechanism of Action Immunomodulators; Interleukin 10 stimulants; Melanocortin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chemotherapy-induced damage; Inflammation; Obesity; Postoperative pain; Type 2 diabetes mellitus

Most Recent Events

  • 13 Aug 2002 Discontinued - Phase-I for Asthma in USA (Inhalation)
  • 13 Aug 2002 Discontinued - Phase-I for Inflammation in USA (Inhalation)
  • 13 Aug 2002 Discontinued - Phase-II for Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top